The holistic 3M modality of drug delivery nanosystems for cancer therapy.

Cancer has become the leading cause of human death worldwide. There are many challenges in the treatment of cancer and the rapidly developing area of nanotechnology has shown great potential to open a new era in cancer therapy. This article, rather than being exhaustive, focuses on the striking progress in the drug delivery nanosystems (DDNS) for cancer therapy and selects typical examples to point out the emerging mode of action of DDNS from our perspective. Among the outstanding advances in DDNS for cancer therapy is the development of "multicomponent delivery systems", "multifunctional nanocarriers" and "multistage delivery systems". However, these represent only one aspect of DDNS research. In addition, nature is the best teacher and natural evolution pressure has meant that virions conform to the "multitarget, multistage and multicomponent" (3M) mode of action. Amazingly, traditional Chinese medicine (TCM), used for over 4000 years in China, also displays the same mode of action. Integrating the previous notable progress in nanoparticle technology, learned from the building mode of natural virions and the action concept of TCM, we propose an integrity-based 3M mode DDNS for cancer therapy: multitarget, multistage and multicomponent, which are not fragmented parts but an interconnected integrity. Based on the physiological multitarget and the pharmacokinetic multistage, multicomponent DDNS are rationally designed, where different components with individual specific functions act in a synergistic manner against each target at each disposition stage to maximize the targeted delivery effectiveness. In this article, we introduce each component of 3M DDNS in detail and describe some typical cases to realize the tumor-homing purposes.

[1]  Lei Han,et al.  Construction of Novel Brain-Targeting Gene Delivery System by Natural Magnetic Nanoparticles , 2011 .

[2]  Xin Gao,et al.  Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. , 2011, Biomaterials.

[3]  Resham Bhattacharya,et al.  Efficient Delivery of Gold Nanoparticles by Dual Receptor Targeting , 2011, Advanced materials.

[4]  Neil Desai,et al.  Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel , 2008, Clinical Cancer Research.

[5]  É. Duguet,et al.  The formation of supported lipid bilayers on silica nanoparticles revealed by cryoelectron microscopy. , 2005, Nano letters.

[6]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[7]  Forrest M Kievit,et al.  Surface engineering of iron oxide nanoparticles for targeted cancer therapy. , 2011, Accounts of chemical research.

[8]  D. Owen,et al.  Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Ick Chan Kwon,et al.  Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[10]  J. Macdiarmid,et al.  Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. , 2011, Current opinion in biotechnology.

[11]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[12]  Mauro Ferrari,et al.  Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. , 2011, Accounts of chemical research.

[13]  Yan Zhang,et al.  Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. , 2011, Molecular pharmaceutics.

[14]  H. Szeto Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents , 2006, The AAPS Journal.

[15]  Xinguo Jiang,et al.  Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. , 2011, International journal of pharmaceutics.

[16]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[17]  R. Jain,et al.  Multistage nanoparticles for improved delivery into tumor tissue. , 2012, Methods in enzymology.

[18]  W. Denny,et al.  Targeting of nanoparticles in cancer: drug delivery and diagnostics , 2011, Anti-cancer drugs.

[19]  Gaurav Sahay,et al.  Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[20]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[21]  H. Kessler,et al.  Ligands for mapping alphavbeta3-integrin expression in vivo. , 2009, Accounts of chemical research.

[22]  L. Gerweck,et al.  Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. , 1996, Cancer research.

[23]  Y. Oh,et al.  Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. , 2011, Biomaterials.

[24]  H. Szeto,et al.  Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury* , 2004, Journal of Biological Chemistry.

[25]  F. Walker Paclitaxel (TAXOL): side effects and patient education issues. , 1993, Seminars in oncology nursing.

[26]  Z. Duan,et al.  Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles , 2008, Clinical Cancer Research.

[27]  Fabio Pastorino,et al.  Targeted Drug Delivery and Penetration Into Solid Tumors , 2012, Medicinal research reviews.

[28]  Mark B. Carter,et al.  The Targeted Delivery of Multicomponent Cargos to Cancer Cells via Nanoporous Particle-Supported Lipid Bilayers , 2011, Nature materials.

[29]  Mark E. Davis,et al.  Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles , 2009, Proceedings of the National Academy of Sciences.

[30]  Jayanth Panyam,et al.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. , 2010, Biomaterials.

[31]  Arjun G. Yodh,et al.  Non-invasive assessment of tumor neovasculature: techniques and clinical applications , 2008, Cancer and Metastasis Reviews.

[32]  N. Pante,et al.  Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. , 2002, Molecular biology of the cell.

[33]  Yang Wang,et al.  Enhancement of the Efficacy of Chemotherapy for Lung Cancer by Simultaneous Suppression of Multidrug Resistance and Antiapoptotic Cellular Defense , 2004, Cancer Research.

[34]  P. Zhang,et al.  Amphiphilic polysaccharide-hydrophobicized graft polymeric micelles for drug delivery nanosystems. , 2011, Current medicinal chemistry.

[35]  J. Xie,et al.  Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. , 2010, Biomaterials.

[36]  Noritada Kaji,et al.  Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. , 2011, Biomaterials.

[37]  S. Vallabhajosula,et al.  Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[39]  Qiang Zhang,et al.  A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[40]  J. Au,et al.  Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. , 2011, Molecular pharmaceutics.

[41]  Wei Liang,et al.  Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. , 2007, Journal of the National Cancer Institute.

[42]  Jeong Hoon Ko,et al.  Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[43]  C Jeffrey Brinker,et al.  Silica nanoparticle supported lipid bilayers for gene delivery. , 2009, Chemical communications.

[44]  Warren C W Chan,et al.  Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. , 2007, Nano letters.

[45]  I. Khalil,et al.  Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[46]  He Lian,et al.  Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. , 2011, International journal of pharmaceutics.

[47]  Yu Zhang,et al.  Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. , 2011, Biomaterials.

[48]  Yu-cheng Tseng,et al.  Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[49]  J. Schellens,et al.  Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma , 2004, Cancer Chemotherapy and Pharmacology.

[50]  D. Jaffray,et al.  APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Christine Allen,et al.  In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[52]  A. Corti,et al.  Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α , 2006, Clinical Cancer Research.

[53]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[54]  L. Huang,et al.  Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. , 1992, Biochimica et biophysica acta.

[55]  J. Israelachvili,et al.  Formation of supported bilayers on silica substrates. , 2009, Langmuir : the ACS journal of surfaces and colloids.

[56]  T. Ishida,et al.  Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[57]  Ajit S Narang,et al.  Role of tumor vascular architecture in drug delivery. , 2011, Advanced drug delivery reviews.

[58]  M. Bally,et al.  In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading , 2004, Clinical Cancer Research.

[59]  D. Welch,et al.  Implications of tumor progression on clinical oncology , 1985, Clinical & Experimental Metastasis.

[60]  Dae-Duk Kim,et al.  Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[61]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[62]  Tatiana Segura,et al.  Utilizing cell-matrix interactions to modulate gene transfer to stem cells inside hyaluronic acid hydrogels. , 2011, Molecular pharmaceutics.

[63]  Ji-Ho Park,et al.  Cooperative nanomaterial system to sensitize, target, and treat tumors , 2009, Proceedings of the National Academy of Sciences.

[64]  C. Klein,et al.  The Metastasis Cascade , 2008, Science.

[65]  H. Szeto Cell-permeable, mitochondrial-targeted, peptide antioxidants , 2006, The AAPS Journal.

[66]  Klaas Nicolay,et al.  Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[67]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[68]  H. Maeda,et al.  Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.

[69]  K. Holmes,et al.  SARS-associated coronavirus. , 2003, The New England journal of medicine.

[70]  H Akita,et al.  Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid , 2007, Gene Therapy.

[71]  Leaf Huang,et al.  Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[72]  Peng Zhang,et al.  Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux. , 2011, Biomaterials.

[73]  X. Wu,et al.  Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[74]  Y. Pei,et al.  PEGylated PAMAM Dendrimer-Doxorubicin Conjugates: In Vitro Evaluation and In Vivo Tumor Accumulation , 2010, Pharmaceutical Research.

[75]  Warren C W Chan,et al.  Nanoparticle-mediated cellular response is size-dependent. , 2008, Nature nanotechnology.

[76]  R. Kurzrock,et al.  Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer , 2007, Molecular Cancer Therapeutics.

[77]  D. Jans,et al.  Using nuclear targeting signals to enhance non‐viral gene transfer , 2002, Immunology and cell biology.

[78]  Rongqin Huang,et al.  Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. , 2011, Biomaterials.

[79]  Omid C Farokhzad,et al.  Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. , 2011, Accounts of chemical research.

[80]  Michael S. Strano,et al.  Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. , 2009, ACS nano.

[81]  V. Labhasetwar,et al.  Targeted Drug Delivery in Cancer Therapy , 2005, Technology in cancer research & treatment.

[82]  Xianghui Xu,et al.  Anti-tumor drug delivery of pH-sensitive poly(ethylene glycol)-poly(L-histidine-)-poly(L-lactide) nanoparticles. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[83]  Angelo Corti,et al.  Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. , 2002, The Journal of clinical investigation.

[84]  Yuexian Liu,et al.  Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. , 2012, Biomaterials.

[85]  S. Rabbani,et al.  Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects , 2007, Anti-cancer drugs.

[86]  Weili Lin,et al.  Hybrid silica nanoparticles for multimodal imaging. , 2007, Angewandte Chemie.

[87]  Rongqin Huang,et al.  Choline‐Derivate‐Modified Nanoparticles for Brain‐Targeting Gene Delivery , 2011, Advanced materials.

[88]  Darrell J Irvine,et al.  Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. , 2007, Nano letters.

[89]  Chen Jiang,et al.  Gene and doxorubicin co-delivery system for targeting therapy of glioma. , 2012, Biomaterials.

[90]  Michael Hawkins,et al.  Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) , 2005, Clinical Cancer Research.

[91]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[92]  B. Stillman,et al.  Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug , 2009, Nature Biotechnology.

[93]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[94]  L. F. Nielsen,et al.  Biodegradable nanocomposite microparticles as drug delivering injectable cell scaffolds. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[95]  Kwangmeyung Kim,et al.  Multi-core vesicle nanoparticles based on vesicle fusion for delivery of chemotherapic drugs. , 2011, Biomaterials.

[96]  Kirsten Sandvig,et al.  Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies , 2011 .

[97]  Ze Lu,et al.  Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. , 2011, Nanomedicine.

[98]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[99]  R. Huang,et al.  Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts , 2010, Leukemia & lymphoma.

[100]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[101]  R K Jain,et al.  Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. , 1994, Cancer research.

[102]  Robert Langer,et al.  Spatiotemporal controlled delivery of nanoparticles to injured vasculature , 2010, Proceedings of the National Academy of Sciences.

[103]  Dai Fukumura,et al.  Multistage nanoparticle delivery system for deep penetration into tumor tissue , 2011, Proceedings of the National Academy of Sciences.

[104]  Peng Zhang,et al.  Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[105]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[106]  Cao Xie,et al.  Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[107]  I. Aoki,et al.  A tumor-environment-responsive nanocarrier that evolves its surface properties upon sensing matrix metalloproteinase-2 and initiates agglomeration to enhance T₂ relaxivity for magnetic resonance imaging. , 2011, Molecular pharmaceutics.

[108]  Goutham Reddy,et al.  Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[109]  Ki-Bum Lee,et al.  Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. , 2011, Molecular pharmaceutics.

[110]  C. Jeffrey Brinker,et al.  Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. , 2009, Journal of the American Chemical Society.

[111]  Christine Allen,et al.  The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. , 2010, Molecular pharmaceutics.

[112]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[113]  S. Mitragotri,et al.  Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. , 2011, Advanced drug delivery reviews.

[114]  A. Levinson Cancer Therapy Reform , 2010, Science.

[115]  Alexander V Kabanov,et al.  Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[116]  Francesco Stellacci,et al.  Effect of surface properties on nanoparticle-cell interactions. , 2010, Small.

[117]  C. Shapiro,et al.  Cardiac safety of liposomal anthracyclines. , 2004, Seminars in oncology.

[118]  M. Dewhirst,et al.  Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.

[119]  Esther H Chang,et al.  Does a targeting ligand influence nanoparticle tumor localization or uptake? , 2008, Trends in biotechnology.

[120]  Xiaoling Fang,et al.  Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. , 2011, Biomaterials.

[121]  Z. Duan,et al.  Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model , 2008, Molecular pharmaceutics.